{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["IsHak WW"],"funding":["NCATS NIH HHS","NIMH NIH HHS"],"pagination":["707-16"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4777696"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["31(8)"],"pubmed_abstract":["<h4>Background</h4>Panic disorder (PD) is highly comorbid with major depressive disorder (MDD) with potential impact on patient-reported outcomes of quality of life (QOL), functioning, and depressive symptom severity.<h4>Methods</h4>Using data from the sequenced treatment alternatives to relieve depression (STAR*D) trial, we compared entry and post-SSRI-treatment QOL, functioning, and depressive symptom severity scores in MDD patients with comorbid PD (MDD+PD) to MDD patients without PD (MDDnoPD). We also compared pre- and posttreatment proportions of patients with severe impairments in quality of life and functioning.<h4>Results</h4>MDD+PD patients experienced significantly lower QOL and functioning and more severe depressive symptoms than MDDnoPD patients at entry. Following treatment wi"],"journal":["Depression and anxiety"],"pubmed_title":["Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial."],"pmcid":["PMC4777696"],"funding_grant_id":["N01 MH090003","UL1 TR000124","N01MH90003"],"pubmed_authors":["Kwock R","Christensen S","Mirocha J","Pi S","Elashoff D","Cohen RM","Akopyan A","Behjat J","Wu F","IsHak WW","Peselow ED"],"additional_accession":[]},"is_claimable":false,"name":"Patient-reported outcomes of quality of life, functioning, and depressive symptom severity in major depressive disorder comorbid with panic disorder before and after SSRI treatment in the star*d trial.","description":"<h4>Background</h4>Panic disorder (PD) is highly comorbid with major depressive disorder (MDD) with potential impact on patient-reported outcomes of quality of life (QOL), functioning, and depressive symptom severity.<h4>Methods</h4>Using data from the sequenced treatment alternatives to relieve depression (STAR*D) trial, we compared entry and post-SSRI-treatment QOL, functioning, and depressive symptom severity scores in MDD patients with comorbid PD (MDD+PD) to MDD patients without PD (MDDnoPD). We also compared pre- and posttreatment proportions of patients with severe impairments in quality of life and functioning.<h4>Results</h4>MDD+PD patients experienced significantly lower QOL and functioning and more severe depressive symptoms than MDDnoPD patients at entry. Following treatment wi","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Aug","modification":"2025-05-29T19:45:06.83Z","creation":"2025-05-29T19:45:06.83Z"},"accession":"S-EPMC4777696","cross_references":{"pubmed":["23861180"],"doi":["10.1002/da.22152"]}}